XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Sales $ 11,402 $ 9,353 $ 22,029 $ 19,641
Costs, Expenses and Other        
Cost of sales 3,104 2,747 6,303 5,576
Selling, general and administrative 2,281 2,085 4,468 4,276
Research and development 4,321 2,085 6,732 4,260
Restructuring costs 82 82 380 152
Other (income) expense, net (103) (387) (558) (325)
Total Costs, Expenses and Other 9,685 6,612 17,325 13,939
Income from Continuing Operations Before Taxes 1,717 2,741 4,704 5,702
Taxes on Income from Continuing Operations 503 396 741 891
Net Income from Continuing Operations 1,214 2,345 3,963 4,811
Less: Net Income (Loss) Attributable to Noncontrolling Interests 1 4 5 (1)
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 1,213 2,341 3,958 4,812
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 332 661 766 1,409
Net Income Attributable to Merck & Co. Inc. $ 1,545 $ 3,002 $ 4,724 $ 6,221
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations $ 0.48 $ 0.93 $ 1.56 $ 1.90
Income from Discontinued Operations 0.13 0.26 0.30 0.56
Net Income 0.61 1.19 1.87 2.46
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations 0.48 0.92 1.56 1.89
Income from Discontinued Operations 0.13 0.26 0.30 0.55
Net Income $ 0.61 $ 1.18 $ 1.86 $ 2.45